Research suggests Pirtobrutinib may provide a ... - CLL Support
Research suggests Pirtobrutinib may provide a safe and manageable risk of bleeding in those requiring antithrombotic therapy
You need to be a member of this community to see this post.
3 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Hypertension and cardiovascular events following ibrutinib initiation
I thought it worth reiterating the high level of hypertension (HT) reported in patients treated...
Second-Generation BTK Inhibitors Hit the Treatment Bullseye With Fewer Off-Target Effects
August 16, 2020
Fewer off-target effects mean second-generation BTK inhibitors offer less...
Ibrutinib Protective against COVID-10 Pulmonary Damage?
I just heard about this today at a forum. A very small convenience sample study of 6 Waldenstrom's...
An Early Look at When CAR-T Therapy Fails Patients With CLL
Not exactly an optimistic report.
Dr James Gerson, MD, - "Not a lot is known as to what happens in...
Progression Free Survival (PFS) post Discontinuation of Ibrutinib in E1912 Trial
An update re the E1912 trial reported at iwCLL this year - "patients who stopped ibrutinib for...
Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell CLL
1.5 million atrial fibrillation cases may be undiagnosed in US (prevalence estimate of 11%)
